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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma that harbors tumor-promoting
properties. No good biomarkers exist to monitor the effect of stromal targeting therapies or to predict response. We
set out to identify such non-invasive markers for PDAC stroma and predict response to therapy. Gene expression
datasets, co-culture experiments, xenografts, and patient samples were analyzed. Serum samples were measured from
a cohort of 58 resected patients, and 87 metastatic or locally advanced PDAC patients. Baseline and follow-up levels
were assessed in 372 additional metastatic PDAC patients who received nab-paclitaxel with gemcitabine (n= 184) or
gemcitabine monotherapy (n= 188) in the phase III MPACT trial. Increased levels of ADAM12 were found in PDAC
patients compared to healthy controls (p < 0.0001, n= 157 and n= 38). High levels of ADAM12 signiﬁcantly associated
with poor outcome in resected PDAC (HR 2.07, p= 0.04). In the MPACT trial survival was signiﬁcantly longer for
patients who received nab-paclitaxel and had undetectable ADAM12 levels before treatment (OS 12.3 m vs 7.9 m p=
0.0046). Consistently undetectable or decreased ADAM12 levels during treatment signiﬁcantly associated with longer
survival as well (OS 14.4 m and 11.2 m, respectively vs 8.3, p= 0.0054). We conclude that ADAM12 is a blood-borne
proxy for stromal activation, the levels of which have prognostic signiﬁcance and correlate with treatment beneﬁt.
Introduction
Survival of patients diagnosed with pancreatic ductal
adenocarcinoma (PDAC) has remained poor for many
decades1. Median survival after diagnosis is around
6 months, and even patients treated with a combination of
surgery and chemotherapy typically succumb to the dis-
ease within 5 years2. The vast majority of patients are
diagnosed with advanced disease, precluding resection of
the tumor. Treatment options for these patients are lim-
ited and clinical trials typically demonstrate only partial
beneﬁt, in a limited number of patients. Biomarkers that
allow patient stratiﬁcation and early response monitoring
are expected to improve outcome.
In recent years, research on PDAC has shifted focus
from tumor cells to the abundant non-malignant com-
partment known as the stroma. This stroma consists of
extracellular matrix proteins, cancer- associated ﬁbro-
blasts (CAFs), and immune cells3. The stroma typically
forms the vast majority of tumor bulk and contributes to
chemoresistance by acting as a barrier to the delivery of
chemotherapeutics. Non-mechanical tumor promoting
properties have been attributed to the stroma as well4.
Nab-paclitaxel is an albumin-bound nanoparticle for-
mulation of paclitaxel that enhances distribution and
penetration into tumor tissues5,6. While the initially sus-
pected role for SPARC (which is expressed on stromal
© The Author(s) 2018
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: M. F. Bijlsma (m.f.bijlsma@amc.uva.nl)
1Amsterdam UMC, University of Amsterdam, LEXOR, Center for Experimental
and Molecular Medicine, Cancer Center Amsterdam, Amsterdam, Netherlands
2Oncode Institute, Meibergdreef 9, 1105AZ Amsterdam, Netherlands
Full list of author information is available at the end of the article.
Equally contributing ﬁrst authors: V. L. Veenstra, H. Damhofer
Equally contributing senior authors: H. W. M. van Laarhoven, M. F. Bijlsma
Oncogenesis
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
1
2
3
4
5
6
7
8
9
0
()
:,;
12
34
56
78
90
()
:,;
ﬁbroblasts and binds albumin) in conferring enhanced
sensitivity to nab-paclitaxel in PDAC was not con-
ﬁrmed7,8. The combination of nab-paclitaxel with gem-
citabine is effective compared to gemcitabine
monotherapy and median survival increases from 6.6 to
8.7 months9. Other stroma targeting agents have also
been tested in trials, but these have failed to demonstrate
favorable outcomes10. Given the practical hurdles to
obtaining tissue from the pancreas for histopathological
assessment, good non-invasive markers are urgently
needed that inform on the PDAC stroma to allow selec-
tion of patients for stroma-targeting therapies, and/or to
monitor the response to such regimens. Currently, there
is a paucity of such markers11.
ADAM12 is a member of the A Disintegrin And
Metalloproteases (ADAM) protein family and harbors
extracellular metalloprotease, and intracellular signaling
properties. The protein is involved in cell adhesion by
binding to integrins and syndecans, as well as the pro-
teolytic cleavage of substrates from producing cells, a
process known as ectodomain shedding12. Cancer-related
substrates of ADAM12 include epidermal growth factor
(EGF), and Sonic Hedgehog (SHH)13–15. Expression of
ADAM12 is elevated in glioblastoma, breast, bladder,
lung, prostate, and liver cancer16–21. ADAM12 expression
correlates with tumor stage in breast and bladder cancer,
and is prognostic in small cell lung cancer16,21,22. A pre-
vious study showed the upregulation of ADAM12 in
pancreatic CAFs compared to ﬁbroblasts from non-
neoplastic tissue, but the clinical or functional relevance
was not explored23. Here, we show that ADAM12 is
associated with the activated stroma, and poor-prognosis
mesenchymal molecular subclasses, in PDAC. It is ele-
vated in the serum of PDAC patients and associates with
poor outcome. In an exploratory analysis of patients
treated with nab-paclitaxel and gemcitabine, circulating
ADAM12 levels predicted outcome.
Results
ADAM12 associates with activated pancreatic cancer
stroma and poor-prognosis molecular subclasses
We identiﬁed ADAM12 in a previous screen for stromal
targets of tumor-derived SHH24. To conﬁrm that
ADAM12 is expressed in human pancreatic cancers, we
queried publically available gene expression datasets that
contain normal pancreas and pancreatic cancer tissue.
ADAM12 was signiﬁcantly higher expressed in tumor
tissue (Fig. 1a and Supplementary Fig. S1a), and high
expression of ADAM12 was associated with worse sur-
vival following resection (Fig. 1b and Supplementary Fig.
S1b)25,26. Microdissected tumor tissue expression data
conﬁrmed a predominantly stromal expression of
ADAM12 (Fig. 1c)27. To further delineate the source of
ADAM12 expression, we measured its expression by
species-speciﬁc qPCR in patient-derived xenografts
(PDXs)28. Mouse Adam12 expression in stromal host cells
was found to be high compared to other well-
characterized paralogs (Adam10 and -17; Fig. 1d)14.
To determine if ADAM12 expression is a hallmark of
tumors with highly activated stromal stellate cells and
(myo)ﬁbroblasts, its correlation with known markers for
such cells was determined by qPCR in bulk tumor tissue
(Fig. 1e, and Supplementary Fig. S2a). A strong correla-
tion of ADAM12 was found with secreted protein acidic
and cysteine rich (SPARC), α-smooth muscle actin
(ACTA2), and ﬁbroblast activation protein (FAP). No
strong inverse correlations with tumor cellularity were
found. Gene set enrichment analysis revealed a signiﬁcant
enrichment of extracellular matrix and stromal pathway
signatures in patients with high ADAM12 expression
(Supplementary Fig. S2b).
Subclasses of PDAC have been deﬁned at the gene
expression level. All current classiﬁcations identify a
subtype that is characterized by mesenchymal features
and increased stromal inﬁltration29. We found that
ADAM12 expression associated with both the Collisson
et al. quasi-mesenchymal30 and the Bailey et al. squamous
subtype tumors31 (Fig. 1f). Patients clustered with the
activated stroma signature from Mofﬁt et al.32 also
showed high expression of ADAM12 (Fig. 1g). These
analyses show that the expression of ADAM12 associates
with poor-prognosis mesenchymal subgroups of PDAC.
ADAM12 expression is driven by tumor cell-derived TGF-β
Several tumor-derived signals have been identiﬁed that
shape the stroma by activating the cells that reside in it.
For instance, transforming growth factor beta (TGF-β) is a
strong activator of CAFs and pancreatic stellate cells
(PSCs) during cancer progression33,34. To functionally
conﬁrm this activation mechanism to drive ADAM12
expression, we treated human stellate cells with TGF-β
and other ligands known to be involved in tumor-stroma
crosstalk. An upregulation of ADAM12 was only apparent
in stellate cells treated with TGF-β (Fig. 2a).
ADAM12 exists as soluble proteins12. These forms can
be generated by shedding of the cell-bound protein, but in
humans a soluble isoform (ADAM12-S) also exists. To
determine if soluble ADAM12 is produced by activated
stellate cells, PS-1 cells were stimulated using TGF-β or
by coculturing with primary PDAC tumor cells, and
ADAM12 was measured by ELISA in the supernatant of
these cultures (Fig. 2b). As for the transcript analysis, a
strong upregulation of ADAM12 was observed following
TGF-β dependent activation of stellate cells. Coculture of
human stellate cells with primary tumor cells led to a
signiﬁcant upregulation of soluble ADAM12 that could be
blocked by the TGF-β pathway inhibitor A83-01, con-
ﬁrming that active TGF-β ligand is present in these
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cocultures and able to drive ADAM12 secretion in stro-
mal cells35.
ADAM12 is elevated in the serum of PDAC patients and
predicts outcome after resection
Having established the association of ADAM12 with
stromal activation and poor-prognosis molecular sub-
classes, we proceeded to evaluate ADAM12 as a non-
invasive biomarker in PDAC. Patients diagnosed with
PDAC before therapeutic intervention showed a sig-
niﬁcant elevation of serum ADAM12 compared to healthy
individuals (Fig. 3a). The association of serum ADAM12
levels with clinical parameters was analyzed (Supple-
mentary Table S1). Patients were dichotomized using
serum ADAM12 levels determined by receiver-operator-
characteristics (ROC, for live-dead resected patients at
time of analysis; 316 pg/ml). No correlations of serum
ADAM12 with age, primary tumor size, and disease stage
were found (Supplementary Table S2). High ADAM12
levels in the resected cohort associated with poor survival
(HR= 2.07, p= 0.041), as did high CA19-9 levels and
high LNR (Table 1). In a multivariate analysis no sig-
niﬁcant associations were found (Supplementary Table
S3). The impact of serum ADAM12 on overall survival
was analyzed by Kaplan–Meier analysis and log-rank test.
We found that whereas serum ADAM12 did not sig-
niﬁcantly associate with survival in unresectable patients,
in resected patients higher ADAM12 levels were strongly
Fig. 1 ADAM12 associates with activated pancreatic cancer stroma and poor-prognosis molecular subclasses. a Boxes indicate median with
ﬁrst and third quartiles of log2 transformed gene expression values from two U133 Plus 2.0 microarray datasets of pancreatic cancer patients
comparing normal and tumor tissue. Badea et al. set (GSE15471), n= 36 paired biopsies; Pei et al. set (GSE16515); n= 16 (normal), n= 36 (tumor).
***p < 0.001, statistical testing was by two-tailed Student’s t test. b Kaplan–Meier analysis of patients from the ICGC cohort, dichotomized for median
ADAM12 expression25. c Log2 transformed ADAM12 expression values from the Pilarksy et al. (E-MEXP-1121)27 gene expression set obtained from
microdissected pancreatic cancer tissue. *p < 0.05, testing by two-tailed Student’s t test. d Transcript levels for indicated Adam/ADAM paralogs relative
to Gapdh/GAPDH were measured in xenografts by qPCR using mouse- or human-speciﬁc primers. Boxplots show data from 10 individual patient
grafts. For each replicate sample measured by qPCR, a technical triplicate was used. Difference between groups was tested by ANOVA for both panels
p < 0.0001. e Association of ADAM12 expression with stromal activation markers in the AMC patient cohort was measured by qRT-PCR, n= 15
patients. Size of dots indicates tumor cellularity scored by a pathologist. f Patients from GSE17891 dataset were grouped by published PDAssigner
subtype labels and log2 expression of ADAM12 and paralog ADAM10 is shown (n= 27). Patients from GSE17891 were grouped by published PC class
labels (n= 96). Difference between groups was tested by ANOVA. g Patients were k-means clustered using the activated stroma gene set and
ADAM12 and -10 expression is shown (n= 132). Difference between groups was tested by ANOVA
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associated with shorter survival (Fig. 3b, c). It thus appears
that activated stroma, as revealed by high serum
ADAM12 levels, contributes to poor disease outcome
when the tumor is at a resectable stage.
ADAM12 levels predict favorable outcome in patients
treated with nab-paclitaxel
The phase III MPACT trial showed survival beneﬁt of
nab-paclitaxel with gemcitabine compared to gemcitabine
in metastasized PDAC patients, and is relatively well
tolerated. To determine if ADAM12 levels associate with
response to nab-paclitaxel, we measured its levels in
plasma samples from the MPACT cohort9,36,37.
Baseline samples were measured and it was observed
that the decreased sensitivity of detection in plasma
(rather than serum) resulted in a considerable number of
samples that had undetectable levels of ADAM12 as
deﬁned by 2 × standard deviation of the optical density of
Fig. 2 ADAM12 expression is induced by tumor cell-derived TGF-β. a Immortalized stellate cells (PS-1)46 were starved with 0.5% FCS for 24 h and
subsequently treated with the indicated ligands for 48 h. Concentrations used: TGF-β, 5 ng/mL; TGF-β receptor I inhibitor A83-01, 1 µM; ShhN
supernatant from 293T cells, 1:4; EGF, 50 ng/ml; bFGF, 10 ng/ml; HGF, 10 ng/ml; IL-1α, 10 ng/ml; IL-1β, 10 ng/ml. In addition to ADAM12, expression
analysis of stromal activation marker genes ACTA and SPARC in response to TGF-β is shown. Two-tailed Student’s t test comparing control vs. TGF-β,
***p < 0.001, **p < 0.001. n= 6, across two separate experiments for control and TGF-b, n= 3 in one experiment for other treatments. For each
replicate sample measured by qPCR, a technical triplicate was used. Bars show mean ± SEM. b To ascertain that tumor cell-derived TGF-β drives
ADAM12 expression, stellate cells were treated as for panel a, or cocultured with tumor cells of the 84 primary culture. Supernatant was harvested
and cleared by centrifugation. Soluble ADAM12 levels were measured by ELISA. At least three replicates are shown, statistical testing was by two-
tailed Student’s t test comparing control vs. TGF-β, and control vs. coculture, ***p < 0.001. n= 6, across two separate experiments for treatments, n=
3 in one experiment for coculture. For each replicate sample measured by qPCR, a technical triplicate was used. Bars show mean ± SEM
Fig. 3 ADAM12 is elevated in the serum of PDAC patients and predicts poor outcome in patients undergoing resection. a ADAM12 levels
were measured by ELISA in serum of healthy individuals (n= 38), and patients diagnosed with PDAC (n= 157). Boxplots show median with
interquartile range. ***p < 0.0001; tested by Mann–Whitney U-test against healthy controls. b Kaplan-Meier survival analysis of AMC PDAC patients
who underwent resection of the tumor, dichotomized by baseline serum levels determined by receiver-operator-characteristics (ROC; 316 pg/mL). c
As for panel b, for patients who did not undergo resection. Statistical testing was by log-rank test
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blanks. Dichotomization of the MPACT cohort by this
cutoff resulted in groups with similar size across treat-
ment arms and baseline characteristics (Supplementary
Table S4 and S5) but signiﬁcantly worse survival for
patients with detectable ADAM12 (Supplementary Fig.
S3a). Univariate Cox regression revealed a HR of 1.41
(1.10–1.81 95% CI; p= 0.0062) for detectable ADAM12
(Supplementary Table S6) in this cohort.
When the trial arms were analyzed separately, ADAM12
levels did not signiﬁcantly associate with survival in
patients that received gemcitabine monotherapy (Fig. 4a,
dashed lines, p= 0.2543). Conversely, in patients that
received nab-paclitaxel with gemcitabine, undetectable
plasma ADAM12 strongly associated with favorable out-
come (solid lines, p= 0.0046). Patients with undetectable
ADAM12 showed a median survival beneﬁt of over
4.0 months from the addition of nab-paclitaxel to gem-
citabine, as compared to a beneﬁt of 1.9 months for
patients with detectable ADAM12. Baseline ADAM12
levels were signiﬁcantly associated with outcome in a
multivariate model including KPS, and treatment as fac-
tors (Supplementary Table S7). Inclusion of CA19.9 in the
model yielded a non-signiﬁcant association of ADAM12
with survival.
Next, we determined the predictive power of the change
in ADAM12 levels during treatment from cycle 1, day 1
(baseline) to cycle 2, day 1 (follow-up) samples (Supple-
mentary Table S4b, baseline characteristics in
Supplementary Table S5b). A reduction in ADAM12
levels is likely to be caused by a diminished stromal
activation, or a reduced tumor load. Indeed, a reduction in
plasma ADAM12 associated with improved survival
(Supplementary Fig. S3b). Importantly, these associations
were all driven by the favorable outcome of patients with
reduced (OS 11.2 m) or repeatedly undetectable (OS
14.4 m) ADAM12 in the nab-paclitaxel with gemcitabine-
treated trial arm, as compared to the increased levels (OS
8.3) of ADAM12 (Fig. 4b, c). Although statistical sig-
niﬁcance was not reached in the gemcitabine arm, the
rank ordering of the groups deﬁned by change in
ADAM12 levels on treatment was the same in both arms
of the trial. In the poorest-outcome group (in which
ADAM12 became detectable or increased at cycle 2), the
overall survival was numerically superior at 8.3 months in
the nab-paclitaxel with gemcitabine arm as compared to
the monotherapy arm at 6.9 months. Thus, our results do
not indicate an absence of treatment beneﬁt from nab-
paclitaxel in the patients with high or increased ADAM12.
In conclusion, we established that ADAM12 is a serum-
borne proxy for the stromal activation of pancreatic
cancers, and that its levels associate with poor disease
outcome. A low level of or decrease in ADAM12 is
associated with improved survival in patients treated with
nab-paclitaxel and gemcitabine, and could possibly be
used to stratify patients in future trials using this or other
treatment combinations.
Table 1 Cox proportional hazard regression model
Univariate Resected Unresectable
HR 95% CI p-value HR 95% CI p-value
Age 1.01 0.97–1.04 0.73 1.02 0.99–1.05 0.203
Gender Male 1 1
Female 0.64 0.31–1.32 0.225 1.32 0.84–2.07 0.236
Stage I 1
II 2.37 0.56–10.01 0.242 1 0.022
III 2.14 0.41–11.12 0.368 1.44 0.59–3.54 0.424
IV 3.86 0.35–42.93 0.273 2.51 1.06–5.99 0.038
Tumor size ≤ 20 mm 1 1
> 20mm 2.01 0.83–4.92 0.124 25.36 0.37–1749 0.134
CA19–9 Low 1 1
High 3.28 1.05–10.19 0.04 2.11 1.21–3.69 0.008
LNR 7.49 1.61–34.89 0.01 n/a n/a n/a
ADAM12 Low 1 1
High 2.07 1.03–4.16 0.041 0.67 0.41–1.10 0.116
Univariate analysis for overall survival in PDAC patients (resected N= 58; unresectable N= 86). Dichotomization of resected patients by CA19-9 was at 415 kU/L, by
ADAM12 at 316 pg/mL. Dichotomization of unresectable patients by CA19-9 was at 354 kU/L. LNR lymph node ratio
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Discussion
PDAC is characterized by an abundance of activated
stroma that harbors both tumor promoting, as well as
suppressive properties38–40. Here, analysis of gene
expression data, patient-derived xenografts and co-culture
experiments identiﬁed ADAM12 as a circulating marker
for activated stroma and tumors of poor-prognosis
molecular subclasses. In patients with resectable disease,
high ADAM12 levels predicted inferior survival out-
comes. This could imply that ADAM12 is not a general
stromal activation marker, but that there are very speciﬁc
biological programs affected by this protein. Known roles
for stromal ADAM12 are manifold: the well characterized
function of ADAM12 as a sheddase of growth factor
receptor ligands such as EGF can provide a nurturing
environment for tumor cells41,42. Furthermore, ADAM12
has been shown to participate in matrix remodeling by
cleavage of extracellular matrix proteins, suggesting
involvement in cancer invasion and metastasis forma-
tion21. Further studies, similar to ones performed for
breast and prostate cancer, are needed to elucidate the
functional contributions of ADAM12 to pancreatic
cancer.
In metastatic PDAC patients treated with gemcitabine,
ADAM12 was not associated with survival. However, low
ADAM12 levels did predict response to treatment in the
cohort of patients treated with nab-paclitaxel and gem-
citabine. This suggests that the supportive role of the
stroma in the metastases predominates, to induce resis-
tance to cytotoxic treatment. In this case, low ADAM12
levels identify lesions that are more sensitive to cytotoxic
treatment. Clearly, such an effect becomes more apparent
in effective treatment regimens, such as nab-paclitaxel
with gemcitabine. Future studies are needed to show that
ADAM12 retains its predictive power for other effective
cytotoxic treatment regimens, such as FOLFIRINOX43.
Alternatively, it could be argued that the stroma-
targeting properties of nab-paclitaxel explain why low
ADAM12 predicts favorable outcome of nab-paclitaxel
and gemcitabine. Nab-paclitaxel is accepted to have at
Fig. 4 Plasma ADAM12 predicts favorable outcome in patients treated with nab-paclitaxel and gemcitabine. a Baseline recalciﬁed plasma
samples from the MPACT cohort were analyzed for ADAM12 and patients were dichotomized for ADAM12 levels above or below detection (2× SD of
blanks). Patients in the arm receiving gemcitabine monotherapy are indicated by dashed lines. Numbers in parentheses indicate number of patients
in the group (n), and median survival for that group (OS). Analysis of patients in the arm receiving gemcitabine and nab-paclitaxel is shown with solid
lines. b Baseline (cycle 1, day 1) and follow-up (cycle 2, day 1) samples were measured and fold change was calculated. Samples with undetectable
ADAM12 levels at both baseline and follow-up did not show a fold change and are indicated by the red line. Patients in the arm receiving
gemcitabine monotherapy are shown. c As for panel b, analysis of patients in the arm receiving gemcitabine and nab-paclitaxel. Statistical testing in
all panels was by log-rank test
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least some degree of speciﬁcity for the stroma: the con-
jugation to albumin has been suspected to increase taxane
concentration at sites of high SPARC (an albumin
receptor) expression such as stromal (myo)ﬁbroblasts6. In
tumors with relatively few activated stromal cells, nab-
paclitaxel will therefore be able to effectively eradicate the
vast majority of the stroma, whereas in tumors with highly
abundant stroma, the ablation is only partial and not
effective in the long term.
One limitation of the current study is the exploratory,
retrospective nature of this analysis. The MPACT trial
was not statistically powered to test the interaction
between serum markers such as ADAM12 and treatment
groups. Furthermore, it is possible that the predictive
value of ADAM12 as inferred from the differences in
response to treatment is a result of the longer survival of
patients receiving nab-paclitaxel with gemcitabine.
Moreover, it should be noted that other biomarker dis-
covery studies have not yet yielded applicable markers.
For instance the initially suspected role for SPARC in
conferring enhanced sensitivity to nab-paclitaxel in PDAC
was not conﬁrmed7,8, and its expression did not correlate
with response to nab-paclitaxel with gemcitabine.
Decreased CA19-9 levels were initially described to
associate with response rate in the experimental arm of
the MPACT trial37, and high baseline CA19.9 was asso-
ciated with reduction in risk of death from the combi-
nation treatment (gemcitabine with nab-paclitaxel)9.
However, in a follow-up analysis CA19-9 levels did not
predict survival in the combination treatment arm36.
Other studies have identiﬁed panels of serum-borne
markers for PDAC stroma and correlated these to
response in experimental models for, but so far, predictive
value has not been assessed11.
Although the signiﬁcant association of serum ADAM12
with outcome was not sustained in multivariate analysis of
the MPACT samples when CA19-9 was included in our
model, levels of ADAM12 were very strongly associated
with favorable responses to nab-paclitaxel with gemcita-
bine suggesting that the analysis of a sufﬁciently large
cohort could conﬁrm predictive power. This will offer
important possibilities for patient stratiﬁcation. ADAM12,
or similar blood-borne proxies for stromal activation
could possibly be used to stratify patients in future trials
with experimental stroma targeting agents, as well as for
currently used (chemo)therapeutics. In summary, we have
shown that ADAM12 expression in pancreatic cancer is
indicative of highly activated stroma as well as poor-
prognosis mesenchymal subclasses of tumors. Systemic
levels of ADAM12 were found to be strongly prognostic
in resectable PDAC patients, and low ADAM12 levels
were associated with improved survival in patients treated
with nab-paclitaxel and gemcitabine. ADAM12, or similar
blood-borne proxies for stromal activation could possibly
be used to stratify patients in future trials with experi-
mental stroma targeting agents, as well as for currently
used (chemo)therapeutics. To deﬁnitively establish the
predictive power of ADAM12 or similar proxies for
stromal activation in solid cancers, we propose a pro-
spective clinical trial, using the levels of such markeres as
intervention to stratify patients for currently available
(chemo)therapeutics, but also experimental stroma tar-
geting agents.
Materials and methods
Collection of blood samples
In the AMC cohort, serum samples were obtained
perioperatively from 60 patients undergoing resection, or
before the start of treatment in case of unresectable
patients (n= 89). Clinicopathological data were obtained
from medical records and included age, gender, tumor
diameter, differentiation grade, lymph node ratio (positive
lymph nodes/total number of lymph nodes examined),
therapies received, and tumor-node-metastasis (TNM)
staging. Collection of material was approved by the
institute’s ethics committee (IRB), and written informed
consent was received from all participants (AMC METC
2014_181)28. Blood samples of 38 non-age matched
healthy individuals without any indication of malignancy
were collected as a control group. In the MPACT trial
cohort, collection of plasma samples for biomarker
development was optional and separate written consent
was obtained for sample collection and biomarker analy-
sis. The patients and methods of the MPACT trial have
been described previously (trial registration number
NCT00844649)37. All patients provided infromed con-
sent. In brief, patients were ≥ 18 years of age, had con-
ﬁrmed measurable metastatic adenocarcinoma of the
pancreas, a Karnofsky performance status (KPS) of ≥ 70,
and did not receive prior chemotherapy for metastatic
disease. Patients were randomized 1:1 (stratiﬁed by per-
formance status, presence of liver metastases, and region)
to receive nab-paclitaxel 125mg/m2 plus gemcitabine
1000 mg/m2 on days 1, 8, and 15 of every 28 days or
gemcitabine alone 1000mg/m2 on days 1, 8, 15, 22, 29, 36,
and 43 in 56 days (cycle 1) and then on days 1, 8, and 15 of
every 28 days (cycle ≥ 2). Treatment continued until dis-
ease progression or unacceptable toxicity.
Establishment of patient-derived xenografts and primary
cell lines
Collection of tumor material was approved by the
institute’s ethics committee in accordance with the
Declaration of Helsinki (AMC METC 2014_181). Written
informed consent was received from all participants28. All
PDAC patients treated in the Academic Medical Center
were diagnosed by pathology or cytology. Specimens were
processed and inspected according to national and
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international guidelines. An experienced pathologist per-
formed microscopic assessment. Final diagnosis was set in
accordance with the WHO classiﬁcation, and the pTNM
classiﬁcation of malignant tumors. Freshly excised tumor
pieces (approximately 3 × 3 × 3mm) originating from the
primary tumor or liver metastasis were washed several
times in PBS containing 10 µg/ml gentamycin (Lonza,
Basel, Switzerland) and 1% penicillin-streptamycin. Pieces
were grafted subcutaneously into the ﬂank of immuno-
compromised NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice (JAX 005557) with Matrigel (BD, Franklin Lakes,
NJ). Both sexes were used, and ages ranged up to
9 months. Animals were bred and maintained at the local
animal facility according to the pertinent legislation, and
ethical approval was obtained for all procedures (DTB/
LEX102348). After outgrowth to a size of ∼500 mm3,
tumors were harvested and passaged, and/or used to
establish in vitro cultures. For this, harvested xenografts
were minced with a scalpel blade, placed in IMDM with
8% FBS and collagenase IV (0.5 mg/ml, Sigma-Aldrich, St.
Louis, MO) and incubated at 37 °C for 60min with vor-
texing every 15min. The dissociated suspension was
passed through a 70 µm cell strainer, washed with culture
medium and grown in IMDM containing 8% FBS and
50 µM β-mercaptoethanol. During the ﬁrst 5–10 passages,
cultures contained colonies of human epithelial cells and
a layer of murine ﬁbroblasts. A culture without epithelial
component, as conﬁrmed by ﬂow cytometry using an
anti-EPCAM antibody (DAKO, F0860 at 1:100), was used
for stimulation experiments. STR proﬁling was performed
to conﬁrm donor-cell line matching (August 2017). For
transcript analysis, all eligible and available xenografts
were analyzed. Randomization and blinding did not apply.
Xenografts were excluded if histopathological assessment
did not conﬁrm diagnosis of PDAC.
RNA isolation and quantitative real-time PCR
Small pieces of PDX tumor were homogenized using an
Ultra-Turrax tissue homogenizer T8 (IKA-Werke, Stau-
fen im Breisgau, Germany) in 1 ml of Trizol (Thermo-
Fisher). Primary cells were lysed in Trizol and RNA
isolation was performed according to the manufacturer’s
protocol. Snap frozen patient tumor samples were
embedded in Tissue-Tek OCT (Sakura FineTek, Japan)
and 30 slices of 20 µm each were cut on a cryotome. Cut
tissue was immersed in 1ml of RNA Bee (Amsbio,
Abingdon, United Kingdom), homogenized, and RNA
isolation was performed according to manufacturer’s
protocol (Qiagen, Hilden, Germany). For tumor percen-
tage scoring, a 10 µm slice was kept before the tissue was
cut in 20 µm slices, and processed for H&E staining.
Scoring of tumor percentage was performed by an
experienced pathologist. cDNA was synthesized using
Superscript III (ThermoFisher) and random primers.
Real-time quantitative RT-PCR was performed with SYBR
green (Roche, Basel, Switzerland) on a Lightcycler LC480
II (Roche). Relative expression of genes was calculated
using the comparative threshold cycle (Cp) method and
values were normalized to reference gene GAPDH/
Gapdh. Primer sequences are: hGAPDH Fw 5′ gaaggt-
gaaggtcggagtc 3′; hGAPDH Rv 5′ tggaagatggtgatgggatt 3′;
hADAM10 Fw 5′ ttcgatgcaaatcaaccaga 3′; hADAM10 Rv
5′ ttccttcccttgcacagtct 3′; hADAM12 Fw 5′ tttccac-
caccctctcagac 3′; hADAM12 Rv 5′ gcctctgaaactctcggttg 3′;
hADAM17 Fw 5′ gggaacatgaggcagtctct 3′; hADAM17 Rv
5′ accgaatgctgctggatatt 3′; hACTA2 Fw 5′ caaagccggcct-
tacagag 3′; hACTA2 Rv 5′ agcccagccaagcactg 3′; hFAP Fw
5′ tcagtgtgagtgctctcattgtat 3′; hFAP Rv 5′
gctgtgcttgccttattggt 3’; hSPARC Fw 5’ gaaagaa-
gatccaggccctc 3′; hSPARC Rv 5′ cttcagactgcccggaga 3′;
hKRT19 Fw 5′ cctggagttctcaatggtgg 3′; hKRT19 Rv 5′
ctagaggtgaagatccgcga 3′; mGapdh Fw 5′ ctcatgacca-
cagtccatgc 3′; mGapdh Rv 5′ cacattgggggtaggaacac 3′;
mAdam10 Fw 5′ aagatggtgttgccgacagt 3′; mAdam10 Rv 5′
tggtcctcatgtgagactgc 3′; mAdam12 Fw 5′ gctttggaggaag-
cacagac 3′; mAdam12 Rv 5′ cgcatcaacgtcttcctttt 3′;
mAdam17 Fw 5′ gtacagcgtgaagtggcaga 3′; mAdam17 Rv
5′ gccccatctgtgttgattct 3′.
Gene set enrichment analysis (GSEA) and expression
analysis
Gene set enrichment analysis (v2.0.14) software was
downloaded from the Broad Institute website (http://
www.broadinstitute.org/gsea) and used according to the
author’s guidelines44. Median ADAM12 expression was
used to dichotomize samples. Gene set for the GO term
‘extracellular matrix’ was downloaded from the Molecular
Signature Database (MSigDB; V4.0); the pancreatic
stroma signature was published by Binkley et al.45 2000
phenotype permutations were used to determine sig-
niﬁcance of the enrichment score. Gene expression data
were collected and processed for use in the AMC in-
house R2 Genomics Analysis and Visualization Platform:
(http://r2.amc.nl). For visualization of gene expression,
data were imported in R and plotted using ggplot2, or
plotted in Graphpad Prism.
Treatment of cultures
Stellate cells (from the Kocher lab46) were seeded in 12-
well culture plates and upon reaching conﬂuence, pre-
starved overnight in 0.5% FBS containing medium and
treated for 24 h with 5 ng/ml recombinant human TGF-
β1 (Peprotech, London, UK) in the presence or absence of
1 µM ALK4/5/7 inhibitor A83-01 (Tocris Bioscience,
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Bristol, UK). ShhN supernatant from 293T cells was
added 1:4, EGF was used at 50 ng/ml, bFGF, 10 ng/ml;
HGF 10 ng/ml; IL-1α, 10 ng/ml; IL-1β, 10 ng/ml. Treat-
ment was not randomized between plate wells, and
experiments were not blinded. Cultures were STR
authenticated (June 2016), and tested for mycoplasma
monthly.
ELISA analysis of serum samples (AMC cohort)
For the reporting on association of ADAM12 levels with
prognosis, the pertinent guidelines were considered47.
Serum was obtained by centrifugation of blood for 10 min
at room temperature at 1300 × g, and storage at −80 °C
until analysis. ADAM12 levels were determined using the
human ADAM12 DuoSet ELISA kit (R&D Systems,
Minneapolis, MN), according to manufacturer’s recom-
mendations. Brieﬂy, after coating the 96-well plates
(Greiner Nunc MaxiSorp, Kremsmünster, Austria) with
capture antibody overnight at room temperature, blocking
the plate with 1% BSA the following day, 80 µl of serum
samples were added. After incubation for two hours at
room temperature and mild washing steps, samples were
incubated with biotinylated detection antibody for addi-
tional two hours followed by a 20min incubation step
with horse-radish peroxidase (HRP)-labeled streptavidin.
Substrate was tetramethylbenzidine substrate solution
(TMB), added for an additional 20 min. Absorbance was
measured at 450 nm and 570 nm with a microplate reader
(BioTek Synergy BioTek, Winooski, VT) after addition of
1M H2SO4 stop solution. For wavelength correction,
570 nm readings were subtracted from the 450 nm values
before further analysis. The technician performing the
analysis was blinded for survival time. Randomization did
not apply.
ELISA analysis of plasma samples (MPACT cohort)
MPACT trial blood samples were collected in EDTA
tubes to chelate calcium and prevent blood clotting, and
storage at −80 °C until analysis. To allow the analysis of
these plasma samples using the ADAM12 DuoSet ELISA,
recalciﬁcation was required. Hundred microliters of
EDTA plasma was complemented with 12mM CaCl2
(ﬁnal concentration) and incubated overnight at 4 °C. The
following day, clots were removed manually and 50 µl
sample was used for the assay. The ELISA was performed
as for the serum samples. Analysis was blinded to the
technician performing the ELISA, who was unaware of the
trial arm the samples were from. Sensitivity of the assay
was reduced compared to measurement in serum by a
factor of 0.44, explaining why in the MPACT cohort, the
lowest quartile was composed of samples that had unde-
tectable plasma ADAM12. Measurement of ADAM12 in
matched serum and plasma samples revealed high cor-
relation (R2= 0.9971, p-value: 2.0 × 10−6, n= 6).
Statistics
Student’s t-tests were performed using GraphPad Prism
5 software (GraphPad, La Jolla, CA). R was used for linear
regression analysis of gene expression. All tests were two-
sided and p < 0.05 was considered statistically signiﬁcant.
Variance was assumed to be similar between compared
groups. Adjustments for multiple comparisons were
applied for gene correlations across the genome (FDR).
For the cell culture experiments, no sample size calcula-
tion was performed. For the AMC cohort patient data,
SPSS package 24 (IBM Analytics, Armonk, NY) was used
for Chi-square testing, Mann–Whitney U test, Spear-
man’s rank correlation, Cox proportional hazard regres-
sion modeling, Kaplan–Meier survival analysis, and log-
rank test. Patients who died within 30 days after operation
were excluded from survival analysis as these likely did
not succumb to cancer (n= 5). Otherwise, all eligible
samples were measured and no power calculation was
performed. Cox proportional hazard regression was used
for univariate and multivariate analyses to investigate the
correlation of OS with ADAM12 and potential prognostic
factors.
For the MPACT cohort, baseline ADAM12 values were
categorized into undetectable (0) and detectable (> 0). The
fold change of ADAM12 at cycle 2, day 1 (C2D1) from
baseline (cycle 1, day 1; C1D1) was calculated by the
results at C2D1 divided by the value at C1D1. These were
then assigned to three groups (0: both values below
detection limit; < 1 if levels decreased, >1 if values
increased). Descriptive statistics summary of demo-
graphics and baseline characteristics were performed.
Correlation of ADAM12 groups with categorical variables
was tested using CMH statistics or Cochran-Armitage
Trend Test statistics, or one-way ANOVA for continuous
variables. All eligible samples were measured and no
power calculation was performed. Overall survival was
analyzed using Kaplan–Meier method and log-rank test.
SAS 9.2 (SAS Institute Inc., Cary, NC) was used for all
statistical analyses in the MPACT study.
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